Jayson Bedford

On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01. The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion. Operational...

Tandem Diabetes Care (NASDAQ: TNDM) remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins are likely to remain “depressed” in the near term, as the company funds...

Johnson & Johnson (NYSE: JNJ) reported a 3% growth in net sales to $24.02 billion, surpassing the consensus estimate of $23.81 billion, and a 4.4% growth in adjusted earnings to $2.59 per share, beating Street expectations of $2.57 per share. Raymond James On Johnson & Johnson: Analyst...

Johnson & Johnson (NYSE: JNJ) stock was on the rise Wednesday following better-than-expected third-quarter earnings and guidance, but analysts are mostly leery of boosting recommendations in light of a string of legal challenges the company faces. The Analysts Morgan Stanley’s...

Johnson & Johnson (NYSE: JNJ) shares are down 2% since the company reported a second-quarter earnings beat on Tuesday morning. Johnson & Johnson reported a 42% increase in net profit in the quarter. Revenue of $20.56 billion was down 1.3% from a year ago but also topped consensus analyst...

Edwards Lifesciences Corp (NYSE: EW) reported Tuesday after the market close with above-consensus first-quarter results and raised its adjusted earnings per share guidance for the full year. The Analysts UBS analyst Matthew Taylor maintained a Neutral rating on Edwards with a $190...

Health care company Abbott Laboratories (NYSE: ABT) has had a strong start to the year with forecast-beating first-quarter results and in-line full-year guidance. The Analyst Raymond James analyst Jayson Bedford maintained an Outperform rating on Abbott with a $79 price target....

Johnson & Johnson (NYSE: JNJ) kickstarted the large-cap pharma earnings season Tuesday with forecast-beating first-quarter results. The company narrowed its full-year earnings per share guidance but maintained its sales outlook. The Analysts Morgan Stanley analyst David Lewis maintained an...

Johnson & Johnson’s (NYSE: JNJ) bottom line continues to be come under pressure from forex and generic competition, and the company faces sentiment-related headwinds, according to Raymond James. These factors are already reflected in the share price, though, and growth is...

Medical device and supplies manufacturer Abbott Laboratories (NYSE: ABT)reported Wednesday ahead of the market open with above-consensus fourth-quarter earnings, while revenue trailed expectations. The Analysts RBC Capital Markets analyst Glen Novarro reiterated an Outperform rating...

Johnson & Johnson (NYSE: JNJ) is on the up after a post-earnings plunge earlier this week. The firm marginally beat guidance in the fourth quarter but issued lower-than-expected guidance. Still, it’s retained the confidence of some Street experts. The Rating Raymond James analyst Jayson...

Raymond James identified four major tailwinds for Insulet Corporation (NASDAQ: PODD) that the firm said could help drive 20-percent-plus revenue growth over the next two years. The Analyst Raymond James analyst Jayson Bedford upgraded Insulet from Market Perform from Outperform with an $80...